HC Wainwright Weighs in on Evolus' Q4 Earnings (NASDAQ:EOLS)

Evolus, Inc. (NASDAQ:EOLS - Free Report) - HC Wainwright raised their Q4 2024 earnings estimates for shares of Evolus in a report issued on Wednesday, January 22nd. HC Wainwright analyst D. Tsao now forecasts that the company will earn $0.00 per share for the quarter, up from their prior estimate of ($0.01). HC Wainwright currently has a "Buy" rating and a $27.00 price objective on the stock. The consensus estimate for Evolus' current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Evolus' Q1 2025 earnings at ($0.04) EPS, Q2 2025 earnings at ($0.02) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at $0.22 EPS, FY2025 earnings at $0.11 EPS, FY2026 earnings at $0.87 EPS, FY2027 earnings at $1.63 EPS and FY2028 earnings at $2.89 EPS.

Separately, Needham & Company LLC reissued a "buy" rating and set a $22.00 price target on shares of Evolus in a report on Tuesday.

Evolus Stock Performance

EOLS stock traded up $0.21 on Friday, hitting $14.23. The company's stock had a trading volume of 747,935 shares, compared to its average volume of 975,409. The firm has a 50 day moving average of $11.79 and a two-hundred day moving average of $13.77. Evolus has a 1 year low of $9.25 and a 1 year high of $17.82. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The stock has a market cap of $901.04 million, a price-to-earnings ratio of -15.64 and a beta of 1.32.

Institutional Trading of Evolus

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Caligan Partners LP lifted its holdings in Evolus by 1.2% in the third quarter. Caligan Partners LP now owns 2,193,488 shares of the company's stock valued at $35,535,000 after acquiring an additional 25,698 shares during the period. Geode Capital Management LLC boosted its holdings in Evolus by 0.9% during the third quarter. Geode Capital Management LLC now owns 1,210,621 shares of the company's stock worth $19,616,000 after buying an additional 11,027 shares in the last quarter. Lord Abbett & CO. LLC grew its position in Evolus by 23.4% during the third quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company's stock worth $16,126,000 after buying an additional 188,685 shares during the period. Assenagon Asset Management S.A. increased its holdings in Evolus by 0.9% in the third quarter. Assenagon Asset Management S.A. now owns 955,555 shares of the company's stock valued at $15,480,000 after buying an additional 8,452 shares in the last quarter. Finally, Rice Hall James & Associates LLC lifted its position in shares of Evolus by 6.3% during the 3rd quarter. Rice Hall James & Associates LLC now owns 904,900 shares of the company's stock valued at $14,659,000 after acquiring an additional 53,605 shares during the period. Hedge funds and other institutional investors own 90.69% of the company's stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.